Teva extends revolving credit facility maturity to April 2028, adjusts leverage covenants

TEVA PHARMACEUTICAL INDUSTRIES LTD

Maturity extended from April 2027 to April 2028 via second one-year extension of the revolving facility.
Maximum leverage ratio set at 4.25x for Q4 2025 and thereafter; can increase 0.5x for acquisitions over $250M.
Covenants suspended if Teva achieves Investment Grade Status (Baa3/BBB- from two agencies); reinstated on loss or default.
Consent fee of 0.08% of total commitments paid to lenders approving the amendment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.